6. Influenza B Yamagata Lineage - Cell culture-derived - Southern Hemisphere 2023
Influenza B Yamagata lineage cell culture-derived candidate vaccine viruses or recombinant vaccine antigen(s) for development and production of vaccines for use in the 2023 southern hemisphere influenza season
20 December 2022
| Technical document
Overview
Human influenza virus isolation using a certified cell line (e.g. MDCK 33016 PFa, NIID-MDCKb) has been performed by WHO Collaborating Centres (CCs) of the WHO Global Influenza Surveillance and Response System (GISRS). The WHO CCs also perform antigenic and genetic analysis on the cell cultured Candidate Vaccine Viruses (ccCVVs). Unless otherwise specified, these ccCVVs have passed two-way haemagglutination inhibition (HI) tests against the cell culture propagated prototype viruses matching the WHO recommendation. No other testing (including adventitious agents) has been performed on these ccCVVs by the WHO CCs. National or regional control authorities generally approve the manufacture, composition and formulation of influenza vaccines used in each country. Manufacturers should consult relevant national or regional control authorities regarding the suitability of using these ccCVVs for influenza vaccine production.WHO Team
Global Influenza Programme (GIP),
Global Influenza Surveillance and Response System